Sumitomo Pharma America, Inc. clinical trials

Acquired by Sumitomo Pharma Co., Ltd., Oct 14, 2009 · source ↗

The registry lists 181 studies whose lead sponsor is Sumitomo Pharma America, Inc.. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 181. List all 181 → · All Sumitomo Pharma Co., Ltd. studies →

• A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's DiseaseRecruitingNCT06753331Phase 1/2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• SMP-3124LP in Adults With Advanced Solid TumorsRecruitingNCT06526819Phase 1/2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of Oral Nuvisertib (TP-3654) in Patients With MyelofibrosisRecruitingNCT04176198Phase 1/2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis PigmentosaRecruitingNCT06891885Phase 1/2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)RecruitingNCT04988555Phase 1/2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood CancersCompletedNCT07444268Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• Study of DSP-0390 in Patients With Recurrent High-Grade GliomaActive, not recruitingNCT05023551Early Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYXCompletedNCT05467176

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide AcetateCompletedNCT05605964Phase 3

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• TP-3654 Food Effect StudyCompletedNCT07492355Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP)Active, not recruitingNCT06517940

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate CancerCompletedNCT04666129Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• Phase 1 Study of Oral TP-1454CompletedNCT04328740Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.CompletedNCT06037668Not applicable

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).TerminatedNCT05227209Phase 3

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.TerminatedNCT05169710Phase 3

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654CompletedNCT06389955Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid TumorsTerminatedNCT03604783Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic ProfileTerminatedNCT03416335Phase 1/2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid TumorsTerminatedNCT03311334Phase 1/2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's DiseaseCompletedNCT02542696Phase 3

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic CancerCompletedNCT02231723Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic AdenocarcinomaCompletedNCT02993731Phase 3

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal CancerCompletedNCT02753127Phase 3

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced MalignanciesCompletedNCT01325441Phase 1/2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed GlioblastomaCompletedNCT02315534Phase 1/2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular CarcinomaCompletedNCT02279719Phase 1/2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 ElevationTerminatedNCT02432690Phase 2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial TherapyCompletedNCT03149003Phase 3

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).CompletedNCT03298984Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction CancerCompletedNCT02178956Phase 3

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal CancerCompletedNCT02024607Phase 1/2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of BBI608 in Adult Patients With Advanced Colorectal CancerCompletedNCT01776307Phase 2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• Alvocidib Biomarker-driven Phase 2 AML StudyTerminatedNCT02520011Phase 2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung CancerTerminatedNCT02826161Phase 3

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal TumorsTerminatedNCT02232620Phase 2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced MalignanciesCompletedNCT02498665Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• Study of TP-3654 in Patients With Advanced Solid TumorsCompletedNCT03715504Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy VolunteersCompletedNCT03411122Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic ProfileTerminatedNCT03416816Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic MalignanciesCompletedNCT02352558Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of BBI503 in Adult Patients With Advanced Urologic MalignanciesWithdrawnNCT02232646Phase 2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• First-in-human Study of Oral TP-0184 in Patients With Advanced Solid TumorsCompletedNCT03429218Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of BBI608 in Adult Patients With Advanced MalignanciesCompletedNCT01775423Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of BBI503 in Adult Patients With Advanced Solid TumorsCompletedNCT01781455Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid TumorsCompletedNCT02729298Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced CancerCompletedNCT02483247Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of BBI503 in Adult Patients With Advanced Hepatobiliary CancerCompletedNCT02232633Phase 2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced CancersCompletedNCT02467361Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination TherapyTerminatedNCT03969420Phase 2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.